Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash & Equivalents: 2014-2025

Historic Cash & Equivalents for AC Immune (ACIU) over the last 10 years, with Sep 2025 value amounting to $34.7 million.

  • AC Immune's Cash & Equivalents fell 7.32% to $34.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.7 million, marking a year-over-year decrease of 7.32%. This contributed to the annual value of $34.7 million for FY2025, which is N/A change from last year.
  • As of Q4 2018, AC Immune's Revenue - Interest and Investment Income stood at $197.9 million, which was up 47.52% from $134.1 million recorded in Q4 2017.
  • Over the past 5 years, AC Immune's Revenue - Interest and Investment Income peaked at $197.9 million during Q4 2018, and registered a low of $80.8 million during Q4 2015.
  • Its 3-year average for Cash & Equivalents is $40.7 million, with a median of $37.4 million in 2024.
  • Per our database at Business Quant, AC Immune's Revenue - Interest and Investment Income soared by 95.25% in 2016 and then fell by 14.98% in 2017.
  • Over the past 4 years, AC Immune's Revenue - Interest and Investment Income (Quarterly) stood at $80.8 million in 2015, then soared by 95.25% to $157.7 million in 2016, then dropped by 14.98% to $134.1 million in 2017, then spiked by 47.52% to $197.9 million in 2018.
  • Its Cash & Equivalents was $34.7 million in Q3 2025, compared to $31,069 in Q2 2025 and $22.2 million in Q1 2025.